Autopsy report · NCT03051607

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

“New Safety Information”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 9 months before it stopped.
• 66 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Biotie Therapies Inc.

Sponsor type

Industry

Conditions

Idiopathic Parkinson Disease

Interventions

Tozadenant

Participants

66

Sites

35

Countries

Canada, United Kingdom, United States

Trials that died the same way

• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (79% match in meaning)
• Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
  “Safety-related” (73% match in meaning)
• A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
  “Safety Review” (72% match in meaning)
• Timing for Removal of Chest Tubes in Adult Cardiac Surgery
  “Safety interim analysis” (69% match in meaning)
• The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
  “Data Safety Monitoring Board concerning of the participants' safety” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.